Ignite Creation Date:
2025-12-24 @ 7:52 PM
Ignite Modification Date:
2026-03-12 @ 10:38 AM
Study NCT ID:
NCT02767804
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-10-14
First Post:
2016-04-30
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Sponsor:
Xcovery Holdings, Inc.
Organization: